Hemab Therapeutics/X
Aug 13, 2025, 09:21
VELORA Discover Study Now Enrolling: Advancing Care for Type 1 Von Willebrand Disease
Hemab Therapeutics shared an inviting post on X:
”Now enrolling people living with Type 1 Von Willebrand disease (VWD) into the VELORA Discover study.
This observational study aims to deepen understanding of Type 1 VWD and help lay the groundwork for future advances in care.
If you are living with Type 1 VWD or treating people who are, learn more about how to participate.”
You can direct your inquiries to [email protected].
Stay informed on all opportunities in the field of bleeding disorders with Hemostasis Today.
-
Aug 21, 2026, 12:08Amy Allen Whitfield: Helping to Proceed Bleeding Disorders Care
-
Aug 21, 2026, 11:53Jan Terje Andersen: Harnessing Placental Biology for Therapeutic Engineering
-
Aug 21, 2026, 11:02Severe ITP, Critical Bleeding, and the Challenge of Platelet Testing – RPTH Journal
-
Aug 21, 2026, 10:46Arwa Z. Al-Riyami: Looking Ahead to ISBT Muscat 2029
-
Aug 21, 2026, 10:42Janine Mothershed: What Is Romiplostim and How Does It Work in Immune Thrombocytopenia?
-
Aug 21, 2026, 10:33Omar Alkharabsheh: Excited to Build the Future of Hematologic Malignancy Care in Central Florida
-
Aug 21, 2026, 10:23Salvador Payán Pernía: Tailoring Therapy in Sickle Cell Disease – Mitapivat and the Path Toward Personalized Combination Care
-
Aug 21, 2026, 10:10Pete Stibbs: The Evolving Landscape of VTE Management
-
Aug 21, 2026, 09:58Nishant K Mishra։ When Epilepsy Meets Anticoagulation